Loading...

Skip to main content

Pfizer Oncology

Overview - by Cancer

Geo Regions

Please verify that you are
a Healthcare Professional

This information is intended for Healthcare Professionals

I am a Healthcare/Medical Professional

I am NOT a Healthcare/Medical Professional

This website is intended for use by Healthcare/Medical Professionals

You will now be re-directed to www.pfizermedicalinformation.com

Please select your location

Africa/Middle East

Asia Pacific

Canada

China

Europe

Japan

Latin America

United States

View studies/programs by

Cancer Type Phase

Cancer types

Breast Cancer (11)

Gastrointestinal Cancer (2)

Genitourinary Cancer (9)

Gynecological Cancer (1)

Hematologic Malignancies (7)

Melanoma (2)

Other or Multiple Cancer Types (24)

Thoracic Cancer (3)

Phases

Phase 1 (46)

Phase 2 (25)

Phase 3 (17)

Study status

Active enrolling

Active Not-enrolling

Breast Cancer

Atirmociclib (PF-07220060)

CDK4 Inhibitor

Phase 1

Phase 2

Phase 3

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor DegraderCDK4 Inhibitor

Phase 1

Phase 2

KAT6 Inhibitor + Atirmociclib (PF-07220060)

PF-07248144CDK4 Inhibitor

Phase 1

CDK2 Inhibitor + Atirmociclib (PF-07220060)

PF-07104091CDK4 Inhibitor

Phase 1

Phase 2

CDK2 Inhibitor

PF-07104091

Phase 1

Phase 2

Felmetatug vedotin (PF-08046048 | SGN-B7H4V)

B7-H4-directed Antibody Drug Conjugate

Phase 1

KAT6 Inhibitor

PF-07248144

Phase 1

Palbociclib

CDK4/6 Inhibitor

Phase 3

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Palbociclib

PROTAC® Estrogen Receptor DegraderCDK4/6 Inhibitor

Phase 1

Phase 2

Phase 3

Tucatinib

HER2 Tyrosine Kinase inhibitor

Phase 1

Phase 2

Phase 3

Vepdegestrant (ARV-471)*

PROTAC® Estrogen Receptor Degrader

Phase 1

Phase 2

Phase 3

Gastrointestinal Cancer

Encorafenib

BRAF Inhibitor

Phase 2

Phase 3

Tucatinib

HER2 Tyrosine Kinase inhibitor

Phase 1

Phase 2

Phase 3

Genitourinary Cancer

Atirmociclib (PF-07220060)

CDK4 Inhibitor

Phase 1

Phase 2

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor DegraderCDK4 Inhibitor

Phase 1

Phase 2

KAT6 Inhibitor + Atirmociclib (PF-07220060)

PF-07248144CDK4 Inhibitor

Phase 1

Disitamab vedotin

HER2-directed Antibody Drug Conjugate

Phase 2

Phase 3

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate

Phase 1

Phase 2

Phase 3

Mevrometostat (PF-06821497) + Enzalutamide

EZH2 InhibitorAndrogen Receptor Inhibitor

Phase 3

Talazoparib + Enzalutamide

PARP InhibitorAndrogen Receptor Inhibitor

Phase 3

KAT6 Inhibitor

PF-07248144

Phase 1

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)

Phase 3

Gynecological Cancer

Tisotumab vedotin

TF-directed Antibody Drug Conjugate

Phase 1

Phase 2

Phase 3

Hematologic Malignancies

Brentuximab vedotin

CD30-directed Antibody Drug Conjugate

Phase 2

Phase 3

CD30-directed Antibody-Glucuronide with TOP1 Inhibitor Payload

PF-08046044 | SGN-35C

Phase 1

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045 | SGN-35T

Phase 1

Elranatamab

BCMA-CD3 Bispecific Antibody

Phase 1

Phase 2

Phase 3

Elranatamab + Maplirpacept (TTI-622 | PF-07901801)

BCMA-CD3 Bispecific AntibodySIRPα-IgG4 Fusion Protein

Phase 1

Maplirpacept (TTI-622 | PF-07901801)

SIRPα-IgG4 Fusion Protein

Phase 1

Phase 2

Non-Fucosylated CD70-directed Antibody

PF-08046040 | SEA-CD70

Phase 1

Melanoma

Encorafenib + Binimetinib

BRAF InhibitorMEK Inhibitor

Phase 2

Phase 3

rotating image for CD228-directed Antibody-Anticalin® Bispecific Protein

CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein

PF-08046049 | SGN-BB228

Phase 1

Other or Multiple Cancer Types

KAT6 Inhibitor + Atirmociclib (PF-07220060)

PF-07248144CDK4 Inhibitor

Phase 1

Atirmociclib (PF-07220060)

CDK4 Inhibitor

Phase 1

Phase 2

Vepdegestrant (ARV-471)* (PROTAC® Estrogen Receptor Degrader) + Atirmociclib (PF-07220060)

PROTAC® Estrogen Receptor DegraderCDK4 Inhibitor

Phase 1

Phase 2

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046052 | SGN-EGFRd2

Phase 1

BRAFi

PF-07799933 | ARRY-440

Phase 1

CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein

PF-08046049 | SGN-BB228

Phase 1

CEACAM5-directed Antibody Drug Conjugate

PF-08046050 | SGN-CEACAM5C

Phase 1

Disitamab vedotin

HER2-directed Antibody Drug Conjugate

Phase 2

Enfortumab vedotin

Nectin-4-directed Antibody Drug Conjugate

Phase 2

Felmetatug vedotin (PF-08046048 | SGN-B7H4V)

B7-H4-directed Antibody Drug Conjugate

Phase 1

Integrin alpha-V/beta-8 Antagonist

PF-06940434

Phase 1

KRAS Inhibitor

PF-07934040

Phase 1

KRAS Inhibitor

PF-07985045

Phase 1

LILRB1/2 Bispecific IgG1 Antibody

PF-07826390

Phase 1

MEK Brain Penetrant Inhibitor

PF-07799544 | ARRY-134

Phase 1

Mesothelin-Targeted Antibody Drug Conjugate

PF-08052666 | SGN-MesoC2

Phase 1

Mevrometostat (PF-06821497)

EZH2 Inhibitor

Phase 1

PD-L1-directed Antibody Drug Conjugate

PF-08046054 | SGN-PDL1V

Phase 1

PD1-IL12

PF-07921585

Phase 1

Sasanlimab

Anti-PD-1 Monoclonal Antibody (mAb)

Phase 2

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate

SGN-B6A

Phase 1

STING Agonist

PF-07820435

Phase 1

Tisotumab vedotin

TF-directed Antibody Drug Conjugate

Phase 2

Tucatinib

HER2 Tyrosine Kinase inhibitor

Phase 2

Thoracic Cancer

Bispecific Gamma Delta-T-Cell Engager Directed to EGFR

PF-08046052 | SGN-EGFRd2

Phase 1

PD-L1-directed Antibody Drug Conjugate

PF-08046054 | SGN-PDL1V

Phase 1

Sigvotatug vedotin

Integrin beta-6 directed Antibody Drug Conjugate

SGN-B6A

Phase 1

Phase 3

Efficacy and safety of these products, for the uses identified within, are currently under investigation. Regulatory approval of any of these products or uses is dependent on the completion of the study programs and review by regulatory authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of February 4, 2025.

Anticalin is a registered US trademark of Pieris Pharmaceuticals Gmbh.

This site is intended for US HCPs and HCPs in countries where accessing this site is permitted

Back to top